Toggle Main Menu Toggle Search

Open Access padlockePrints

A critical overview on ticagrelor in acute coronary syndromes

Lookup NU author(s): Dr Vijay Kunadian


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.

Publication metadata

Author(s): Navarese EP, Buffon A, Kozinski M, Obonska K, Rychter M, Kunadian V, Austin D, De Servi S, Sukiennik A, Kubica J

Publication type: Review

Publication status: Published

Journal: QJM: An International Journal of Medicine

Year: 2013

Volume: 106

Issue: 2

Pages: 105-115

Print publication date: 01/02/2013

ISSN (print): 1460-2725

ISSN (electronic):



DOI: 10.1093/qjmed/hcs187


Find at Newcastle University icon    Link to this publication